Corcept Therapeutics Incorporated (CORT) Insider Trading Activity

Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable. The company's development pipeline is robust, featuring relacorilant, which is being advanced for Cushing's syndrome. It is also investigating a combination of relacorilant with nab-paclitaxel; this pairing has concluded Phase II clinical trials for advanced ovarian tumors and is additionally being studied for conditions involving cortisol excess. Furthermore, Corcept is developing distinct selective cortisol modulators for specific indications such as metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain, alongside research into FKBP5 gene expression assays.

Show less

Over the last 12 months, insiders at Corcept Therapeutics Incorporated have bought $3.31M and sold $58.09M worth of Corcept Therapeutics Incorporated stock.

On average, over the past 5 years, insiders at Corcept Therapeutics Incorporated have bought $3.27M and sold $29.97M worth of stock each year.

Highest buying activity among insiders over the last 12 months: BAKER G LEONARD JR (director) — $3.31M.

The last purchase of 100,000 shares for transaction amount of $3.31M was made by BAKER G LEONARD JR (director) on 2026‑03‑17.